Therapy with mesenchymal stem cell transplantation in multiple sclerosis is ready for prime time: No

Abstract

Get full access to this article

View all access options for this article.

References

Bai

Lennon

Caplan

, et al. Hepatocyte growth factor mediates mesenchymal stem cell–induced recovery in multiple sclerosis models. Nat Neurosci 2012; 15(6): 862–870.

Zappia

Casazza

Pedemonte

, et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005; 106(5): 1755–1761.

Uccelli

Laroni

Freedman

. Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases. Lancet Neurol 2011; 10(7): 649–656.

Freedman

Bar-Or

Atkins

, et al. The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: Consensus report of the International MSCT Study Group. Mult Scler 2010; 16(4): 503–510.

Connick

Kolappan

Crawley

, et al. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: An open-label phase 2a proof-of-concept study. Lancet Neurol 2012; 11(2): 150–156.

Van den Bos

Ouaamari

Wouters

, et al. Are cell-based therapies safe and effective in the treatment of neurodegenerative diseases? A systematic review with meta-analysis. Biomolecules 2022; 12(2): 340.

Petrou

Kassis

Levin

, et al. Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis. Brain 2020; 143(12): 3574–3588.

Uccelli

Laroni

Ali

, et al. Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): A phase 2, randomised, double-blind crossover trial. Lancet Neurol 2021; 20(11): 917–929.

Mohyeddin Bonab

Yazdanbakhsh

Lotfi

, et al. Does mesenchymal stem cell therapy help multiple sclerosis patients? Report of a pilot study. Iran J Immunol 2007; 4(1): 50–57.